mitomycin / Generic mfg. - LARVOL DELTA

PHASE 3 STUDY OF TAR-210 INTRAVESICAL ERDAFITINI RELEASING SYSTEM VS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–TREATED HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER WITH SUSCEPTIBLE FGFR ALTERATIONS (AUA 2025) - "Approximately 220 pts will be randomized 1:1 to receive TAR-210 or investigator's choice of either IVES mitomycin C (MMC) or gemcitabine. Assessments will be based on urine cytology, bladder biopsy, and imaging. Enrollment is expected to open in 2025."

Clinical • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • FGFR

Prediction of Prognosis, Tumor Microenvironment, and Drug Treatment of Colorectal Cancer Based on Retinoic Acid-Related Genes. (PubMed, J Environ Pathol Toxicol Oncol) - "Drug sensitivity prediction results revealed that AZ628, CGP-082996, CKM, Dasatinib, GNF-2, Saracatinib, Sorafenib, WH-4-023, and WZ-1-84 were more sensitive for patients in the HR group. AKT inhibitor VIII, Gemcitabine, JW-7-52-1, Mitomycin, NSC-87877, PAC-1, Pyrimethamine, QS11, and Roscovitine were more sensitive for those in the LR group. Our project identified correlations between RA-related genes and CRC. The model genes identified are essential indicators for evaluating CRC prognosis and further treating CRC."

Biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor

Unraveling the rarity: p16-positive and p53-positive locally advanced anal cancer in a person living with HIV. (PubMed, J Infect Dev Ctries) - "This case illustrates the challenges of managing ASCC in PLWH and underscores the need for optimized CRT protocols for this population. Reliable molecular biomarkers, including p16, p53, and Ki-67, may guide personalized therapy and improve prognostic stratification."

Journal • Anal Carcinoma • Dermatitis • Dermatology • Fibrosis • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Leukopenia • Novel Coronavirus Disease • Oncology • Palliative care • Solid Tumor • Squamous Cell Carcinoma • TP53

Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report. (PubMed, Urol Case Rep) - "We report a 78-year-old man with recurrent high-risk NMIBC and PUI after bacillus Calmette-Guérin and mitomycin C. Blue-light cystoscopy (BLC) during restaging identified additional carcinoma in situ and high-grade T1 disease not seen with white light...Despite favorable findings, the patient elected radical cystectomy, which revealed no residual tumor. This case highlights the complementary roles of BLC and ctDNA."

Circulating tumor DNA • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer

Rapid Pterygium Progression in a Child on Growth Hormone Therapy: A Case Report and Literature Review. (PubMed, Cureus) - "The patient underwent pterygium excision with mitomycin C and amniotic membrane grafting...Given the established presence of GH and GH receptors in ocular tissues, clinicians should consider GH therapy as a possible contributing factor when evaluating pediatric patients with progressive ocular surface lesions such as pterygium. Further research is needed to clarify the role of endocrine signaling in pterygium pathogenesis."

Journal • Astigmatism • Inflammation • Ophthalmology • Pediatrics

Inferior exten filtering bleb formation after laser goniopuncture in a patient with conjunctivochalasis. (PubMed, Am J Ophthalmol Case Rep) - "A 66-year-old man with advanced primary open-angle glaucoma underwent combined phacoemulsification, deep sclerectomy, and intraoperative mitomycin C in the right eye...While self-limiting here, such morphology could have implications for comfort, contact lens use, or hypotony risk. Pre-existing conjunctival redundancy may influence postoperative bleb morphology and should be considered in surgical planning and follow-up after bleb-forming glaucoma surgeries."

Journal • Glaucoma • Ophthalmology

Rationale and study design of the KOV-HIPEC-02R (RECOVER): A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer (ESGO 2026) - P3 | "After cytoreductive surgery, patients undergo the HIPEC procedure at 41.5°C, with doxorubicin at 35mg/ m2 and mitomycin at 15mg/m2. As of October 31, 2025, 140 patients (100%) have been randomized. Results There are no available results at the time of submissionConclusion The role of cytoreductive surgery and HIPEC in platinum-resistant recurrent ovarian cancer will be elucidated for the first time through this randomized trial (KOV-02R, RECOVER)."

Clinical • P3 data • Platinum resistant • Surgery • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Comparison of disease-free survival, overall survival, and complications between patients with advanced ovarian cancer receiving neoadjuvant systemic chemotherapy with or without HIPEC (ESGO 2026) - "HIPEC was performed using the closed technique with cisplatin 75 mg/m² and mitomycin 10 mg/m² at 41–43 °C for 90 minutes. Severe postoperative complications (Clavien–Dindo ≥ III) were rare in both groups.Conclusion HIPEC appears feasible and safe in advanced ovarian cancer without increasing severe complications. Although long-term DFS favoured the HIPEC group, further randomised trials are warranted to confirm survival benefit and standardise protocols."

Clinical • Metastases • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

VNOTES PIPAC in a patient with a gastric krukenberg tumor (ESGO 2026) - "Simultaneously, intravaginal pressurized intraperitoneal aerosol chemotherapy (PIPAC) with mitomycin was performed...We believe this approach is safe, feasible, and advantageous in terms of postoperative recovery time. Conclusion This technique should be evaluated in larger case series in appropriate patients."

Clinical • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor

Integrative analysis of therapeutic modalities in mucinous ovarian carcinoma associated with pseudomyxoma peritonei: A systematic review and meta-analysis (ESGO 2026) - "No survival difference was observed between mitomycin-C and oxaliplatin-based HIPEC (HR 1.08; 95% CI 0.84–1.41). Conclusion Maximal cytoreductive surgery followed by HIPEC constitutes the optimal therapeutic approach for resectable MOC–PP, achieving durable survival with acceptable morbidity. Integration of molecular profiling, particularly KRAS and GNAS status, should guide future genotype-driven systemic strategies and standardised prospective trials."

Retrospective data • Review • Oncology • Ovarian Cancer • Solid Tumor • GNAS • KRAS

SEOM-GEMCAD-TTD clinical guidelines for anal cancer (2025). (PubMed, Clin Transl Oncol) - "When clinical suspicion of anal cancer exists, histological confirmation, correct local staging with MRI and distant staging with thoraco-abdominal CT, and management by a multidisciplinary team are mandatory. Chemoradiotherapy with 5-FU and mitomycin C (MMC) is the standard of care for early and locally advanced disease, while combination chemotherapy with a platinum-containing compound and taxanes is the treatment of choice for metastatic disease."

Clinical guideline • Journal • Anal Carcinoma • Oncology • Solid Tumor

Tailoring of metal organic framework with electrospun polyacrylonitrile for on-chip electromembrane extraction and determination of anticancer drugs in biological samples. (PubMed, Mikrochim Acta) - "An on-chip electromembrane extraction integrated with solid-phase microextraction (EME-SPME) was developed for the determination and monitoring of anticancer drugs, including imatinib, irinotecan, and mitomycin C, in various biological fluids. The applicability of the system was investigated through the extraction of target analytes from human urine and plasma samples, yielding relative recoveries between 78 and 110%. These results highlight the potential of the developed EME-SPME platform as a sensitive, precise, and environmentally friendly technique for therapeutic drug monitoring of anticancer agents in complex biological matrices."

Journal • Oncology

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). (PubMed, Eur Urol) - "BCG + MM was not proved superior to BCG alone, but required 39% fewer doses of BCG and fewer treatment discontinuations. These findings support consideration of BCG + MM as a pragmatic alternative to BCG alone, which could mitigate the global shortage of BCG."

Journal • P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. (PubMed, Ann Surg Oncol) - "CMS4 exhibits distinct drug sensitivity patterns that could guide personalized HIPEC agent selection. This may explain the success of mitomycin-C and the limited efficacy of oxaliplatin in HIPEC trials. Future clinical trials should consider genomic subtyping and drug sensitivity testing to guide personalized HIPEC strategies for patients with CRC-PM."

Journal • Colorectal Cancer • Oncology • Solid Tumor

Adaptive Radiation in Anal Cancer (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Columbia University | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • Anal Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

Vancomycin/mitomycin C conjugate as a broad spectrum antimicrobial targeted drug therapy (ESCMID Global 2026) - No abstract available

Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC. (PubMed, Clin Epigenetics) - "SAHA imposes a common anti-proliferative core but engages distinct lineage-conditioned risk modules in LUAD and LUSC-cell-cycle/migration-linked in LUAD and checkpoint/stress-linked in LUSC. These SAHA feature-sensing modules provide a mechanistic and clinically anchored framework for subtype-tailored HDAC-directed combinations and for future development of HDACi-aligned biomarkers in NSCLC."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • ANXA5 • HDAC4 • HDAC7 • KRAS • PDGFRA

IMGeS study: A prospective, multicentre, phase II trial of sequential intravesical mitomycin-C and gemcitabine therapy in BCG-unresponsive high-risk NMIBC ineligible for or declining radical cystectomy. (ASCO-GU 2026) - P2 | "Clinical Trial Registry Number: NCT06388720. The full, final text of this abstract will be available on Feb 23 at 05:00 PM EST."

Clinical • P2 data • Bladder Cancer • Genito-urinary Cancer

Efficacy and safety of disitamab vedotin combined with intravesical electromotive mitomycin-C in patients with HER2-expressing high-risk non–muscle-invasive bladder cancer: A phase II study. (ASCO-GU 2026) - "Research Funding National Cancer Center Climbing Fund. The full, final text of this abstract will be available on Feb 23 at 05:00 PM EST."

Clinical • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial. (ASCO-GU 2026) - P2 | "Clinical Trial Registry Number: NCT03058757. The full, final text of this abstract will be available on Feb 23 at 05:00 PM EST."

Clinical • Clinical data • P2 data • Bladder Cancer • Genito-urinary Cancer

Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301). (ASCO 2025) - P3 | "BCG+MM had similar efficacy and safety, but with fewer treatment discontinuations and fewer doses of BCG than BCG-alone. BCG+MM is a good alternative to BCG-alone."

Clinical • Late-breaking abstract • P3 data • Bladder Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Clinical trial on the effectiveness of intravesical hematoporphyrin infusion photodynamic therapy combined with intravesical mitomycin in the treatment of high-risk nonmuscular invasive bladder cancer (ChiCTR) - P4 | N=123 | Not yet recruiting | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New P4 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Mitomycin C-Based Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Colorectal Cancer With Peritoneal Metastasis. (PubMed, Cureus) - "CRS combined with MMC-based HIPEC provides a significant survival benefit for selected patients with colorectal cancer and isolated peritoneal metastasis. These findings support the role of MMC-based HIPEC as an effective locoregional treatment strategy."

Journal • Colorectal Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Comparing the Effects of Mitomycin-C and Triamcinolone-Acetonide Injections on Hypertrophic Scars and Keloids in Burn Patients. (PubMed, World J Plast Surg) - "MMC and TAC were considered as effective methods for HTS and keloid management. In spite of this, the VSS scores and the scar size denoted that MMC was much more effective in the treatment of such scars than TAC."

Clinical • Journal • Fibrosis

The Genetic and Molecular Analyses of Rare Candidate Germline BRIP1/FANCJ Variants Implicated in Hereditary Breast and Ovarian Cancers. (PubMed, Int J Mol Sci) - "Of the five reported BRIP1 variants, p.Thr266Met, p.Pro696Leu and c.2990_2993delCAAA; p.Thr997ArgfsTer61, which were predicted to be damaging, conferred cellular sensitivity to mitomycin C and cisplatin unlike p.Ser139Ala and p.Ala406Ser. Collectively, our investigation implicates BRIP1 c.797C>T; p.Thr266Met, c.2087C>T; p.Pro696Leu and c.2990_2993delCAAA; p.Thr997ArgfsTer61 as deleterious variants in OC and BC."

Journal • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRIP1